Search

The authors have evaluated the AlphaCor artificial cornea (previously Chirila KPro) in human patients since 1998, utilizing an intrastromal technique requiring extensive corneal lamellar dissection and recommending conjunctival flaps in all cases. Recent availability of low-profile instruments has facilitated a simpler technique, which was first evaluated in two subjects followed for over 1 year prior to recommending the technique for wider adoption. The new technique is presented and illustrated herein, and its benefits and limitations compared with the traditional AlphaCor implantation are discussed. [ABSTRACT FROM AUTHOR]

: ObjectiveTo undertake a preliminary safety and performance evaluation of an artificial cornea, the Chirila Keratoprosthesis, in human patients.: DesignA prospective, interventional case series.: ParticipantsFourteen consecutive patients with blindness of corneal origin not treatable by repeated standard penetrating keratoplasty.: MethodsKeratoprostheses were manufactured and implanted. The patients, all with preoperative visual acuity of light perception to count fingers (CF), were followed clinically in adherence to a protocol.: Main outcome measuresSafety (keratoprosthesis retention, incidence of serious complications) and performance (visual acuity, comfort, appearance).: ResultsNinety-three percent of keratoprostheses were retained to the date of reporting, up to 2.5 years. One keratoprosthesis (7%) was removed in a manner that restored the patient’s preoperative condition. All but one patient maintained their preoperative level of visual acuity or improved on it, with most achieving their estimated full potential visual acuity, (range, count fingers – 20/20).: ConclusionsThis keratoprosthesis is acceptably safe and has demonstrated an ability to restore vision in cases in which alternative management would have had a poor prognosis. More extensive trials are warranted. [Copyright &y& Elsevier]